Abbott has recently received regulatory approval for the first denosumab biosimilar in Thailand, a significant development that is set to broaden access to treatment for bone diseases such as osteoporosis. Karim Elmashad, the divisional vice president of Abbott’s medicines business in Asia Pacific, emphasized the transformative impact that denosumab biologics can have on individuals dealing with osteoporosis or cancer-related bone diseases. By securing this approval, Abbott is facilitating greater accessibility to this innovative therapy for individuals in Thailand grappling with these challenging conditions.
Osteoporosis is a chronic and age-related disease that poses a notable public health concern, particularly due to its debilitating consequences such as fractures that can result in a loss of independence and diminished quality of life. Statistics reveal that in Thailand, the prevalence of osteoporosis is significant, affecting approximately 1 in 5 women and 1 in 10 men, with a higher incidence among the elderly population. As Thailand’s demographic shifts towards an aging society, with projections indicating that 25% of the population will be aged 60 or older in the coming decade, the burden of osteoporosis-related fractures, disability, and healthcare expenditures is anticipated to escalate.
Despite the severe implications of osteoporotic fractures, less than 40% of hip fracture patients in Thailand commence anti-osteoporosis therapy, often due to barriers such as financial constraints, lack of awareness, and limited treatment options. Abbott’s initiative to offer denosumab in Thailand aligns with its overarching strategy to enhance access to premium-quality medicines in crucial therapeutic areas like oncology, immunology, and women’s health through strategic collaborations with biotechnology firms. Leveraging its extensive 135-year legacy in delivering impactful healthcare solutions, Abbott’s foray into biosimilars in regions like Latin America, India, Malaysia, and now Thailand underscores its commitment to addressing the mounting burden of chronic illnesses in the Asia-Pacific region while ensuring affordability of top-notch treatments.
By introducing denosumab in Thailand, Abbott is not only catering to the pressing healthcare needs of the country’s population but also paving the way for a more inclusive and equitable healthcare landscape by offering high-quality treatments at more accessible prices. This strategic move resonates with Abbott’s core mission of enabling individuals to lead healthier and more fulfilling lives across all life stages. With a global presence in over 160 countries, Abbott’s diverse portfolio of healthcare technologies encompasses diagnostics, medical devices, nutritional products, and branded generic medicines, all aimed at enriching the well-being of people worldwide.
As Abbott expands its footprint in the biosimilars arena, particularly in the Asia-Pacific region, the approval of the denosumab biosimilar in Thailand stands as a notable milestone in the company’s journey to democratize access to advanced healthcare solutions. Through its unwavering dedication to innovation, affordability, and patient-centered care, Abbott is poised to make a lasting impact on the healthcare landscape, empowering individuals to embrace healthier lifestyles and achieve better health outcomes.
- Abbott’s regulatory approval for the denosumab biosimilar in Thailand signifies a significant stride towards enhancing access to bone disease treatment in the region.
- The introduction of denosumab in Thailand addresses the pressing healthcare needs of a population grappling with a high prevalence of osteoporosis, especially among the elderly.
- Abbott’s commitment to expanding access to high-quality medicines through strategic partnerships underscores its dedication to improving healthcare outcomes and affordability.
- This milestone not only reflects Abbott’s rich legacy of healthcare innovation but also signals a promising future for individuals in Thailand seeking transformative therapies for bone diseases.
Tags: biosimilars, regulatory
Read more on manilatimes.net